Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S.

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug pricing deals.

Starting Jan. 1, 2026, Medicare will slash prices on 10 common drugs for heart disease, diabetes, and more. See if your ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options ...

The post The FDA Often Doesn’t Test Generic Drugs for Quality Concerns, So ProPublica Did appeared first on ProPublica.

Forbes contributors publish independent expert analyses and insights. The U.S. spent $722.5 billion on pharmaceuticals in 2023. Although brand-name drugs consume four out of every 5 dollars America ...

Supply from drugmakers for the stimulant medications most commonly prescribed for ADHD are still falling short of demand, the Food and Drug Administration says, and many Americans who rely on these ...

Generic drug manufacturers are facing increasing pressure from drug distributors, pharmacy benefit managers, and Indian competitors, leading to downward trends in generic drug prices. Which firms are ...

Generic drugs account for more than 90 percent of prescriptions filled in the United States. Recent studies have found concering variability in quality and safety America’s generic drug supply, most ...

Ever since President Donald Trump started promising to slap tariffs on pharmaceutical imports, drugmakers have unveiled a flurry of commitments to build or expand US manufacturing operations in the ...